#ACR21 Ab#1942. RABBIT: Non-melanomatous skin ca on DMARD Multivariable analysis: 👉Adjusted HR for Abatacept HR ~2 Risk of co-medication with MTX needs further investigation https://t.co/JOKNyYVZfX @Rheumnow https://t.co/DyG5hbOc8Z

• https://bit.ly/3mZFaCz

#Abatacept gives more skin cancers in #RheumatoidArthritis from RABBIT registry? pts in Abatacept had more comorbidity? Channeling bias. Who knows. Abst#1942 #ACR21 @RheumNow

Wanna know more about the relation between 🌦🌩 and RA disease activity? It's below 👇🏻 https://t.co/oUC7lrTEwF #Abst1912 #ACR21 @RheumNow https://t.co/3iJra047gC

• "Doctor, I Can Tell When It's Raining!" - Dr. Aurelie Najm | Rhe…

COREVITAS registry 600+ PsA/SpA pts 7yrs follow-up TNFi ❗️Overall low persistency 39% at 2 yrs ❕TNFi persistency = across 6 disease domains ❗️Shorter treatment duration if Enthesitis or Ax PsA #ACR21 #Abst1818 @RheumNow https://t.co/1aE8eWn4TD

NOR-DRUM B: infliximab therapeutic drug monitoring (TDM) vs standard of care (SoC) Goal inflix. level 3.0-8.0mg/L 🔹axSpA, PsA, PsO, RA, UC, Crohns 🔹Dose⬆️or⬇️based on how level & +/- inflix-Ab 🔹Proactive TDM superior https://t.co/BHQwJSVHxD #ACR21 Abst#1946 @RheumNow #ACRBest

• Therapeutic Drug Monitoring Compared to Standard Infliximab Therapy in Patients…

Oh, also VTEs. Not designed to do this, but: - We don't use 10mg bid & we shouldn't start - 5mg bid looks just fine - In fact, in patients with a VTE history, 5mg bid is numerically similar (?better) to TNFi Somehow, VTE in tofa is an overshadowed non-event! #ACR21 @RheumNow https://t.co/fvMSg49kk6

So today the full NOR-DRUM B details - the first positive RCT for TNFi TDM in rheum HR 2.09 for worsening with standard care (clinician discretion) vs proactive TDM (change before clinical issue) Open label, but this is a lot better than guessing! #ACR21 ABST1946 @RheumNow https://t.co/kyKh00ARVW https://t.co/uW6vYHLI7Y

• David Liew on Twitter: "oh wait!
no photos, but NOR-DRUM B results:&#1…

Different drugs may target different pathways in PsA! S-cell proteomic biomarkers in SELECT-1 PsA study: 💥UPA targets ▶️ Adaptive immunity, bone metabolism pathways 💥ADA targets ▶️ innate immunity pathways. Paving the ground for personalised therapy? #ACR21 #Abst1816 @RheumNow https://t.co/hyMP4PtUnM

An artificial neural network for detection of radiographic #sacroiliitis in axSpA? @DrPoddubnyy 📌Specificity - 93.9% 📌Sensitivity - 78.7% Potential tool for interpreting SIJ in nonspecialized ctrs or clinical trials This is a game changer!🤓 @RheumNow #ACR21 #ACRBest abs1919 https://t.co/2li0dNWtLc

And it’s a wrap!! Time for a pool game🎱 Delighted to have been reporting for @RheumNow alongside an amazing faculty! and delighted to have been able to be around amazing colleagues to attend #ACR21 convergence! See you all next year, hopefully for real! 🤞🏼 https://t.co/JBoKd7zNvl

Abstr 1677 Miwa & colleagues studied the effect of bDMARDs on cholesterol levels in RA patients - bDMARDs may affect HDL levels - no significant effect was seen on LDL #ACR21 @RheumNow https://t.co/yb35HMDlxN

Bridging the gap in the delayed diagnosis of axSpA Dr. Swetha Ann Alexander ( @swethaann23 ) shares the findings from several abstracts presented at #ACR21. https://t.co/8eEXIbyopA https://t.co/brtaZztRhl

• https://bit.ly/3CWbV9u

RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow and its faculty.

Increased Risk of MACE in Lupus After Noncardiac Surgery: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #0128 presented at #ACR21 annual meeting. https://t.co/HOVLrhBbuu https://t.co/MAItCSHMIb

• https://bit.ly/3BWpAvT